It appears that Mesoblast has also completed the submission of its rolling BLA to the FDA for approval of its product candidate for acute gvhd.
From today's anouncement:
About MesoblastSee below for comparison:
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the- shelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast completed submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates.
From previous announcement dated 27/11/2019 (Mesoblast Chairman Message to 2019 AGM)
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-theshelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast has initiated submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial, and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates. Mesoblast’s proprietary manufacturing process yields industrial-scale, frozen, off-the
You can verify the abvove info yourself by reading these two announcements.
- Forums
- ASX - By Stock
- Submission of rolling BLA to the FDA for acute GVHD completed
It appears that Mesoblast has also completed the submission of...
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 50400 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | 1.300 |
6 | 101986 | 1.295 |
6 | 226866 | 1.290 |
4 | 70613 | 1.285 |
5 | 137074 | 1.280 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 50400 | 2 |
1.315 | 2007 | 1 |
1.320 | 40992 | 3 |
1.325 | 20772 | 3 |
1.330 | 139522 | 8 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online